Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study

An interesting article from Sørensen et al. about long term survival from childhood ALL (acute lymphoblastic leukemia). According to this article the long term results have improved decade after decade. Still there is space for improvements. Even if it is a small part of the whole ALL treatment protocol, it is worth having the lumbar punctures right the first time.

“Among ALL survivors, it was found that late mortality continued to decrease over treatment decades. This was highly attributable to a decrease in mortality from relapse.”

Read the publication from here: Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study Pediatr Blood Cancer. 2022;

Gitte V. Sørensen1,2 Federica Belmonte3 Friederike Erdmann4,5 Hanna Mogensen6 Vanna Albieri3 Anna S. Holmqvist7 Laura Madanat-Harjuoja8 Mats Talbäck6 Mats M. Heyman9 Nea Malila8 Maria Feychting6
Kjeld Schmiegelow10 Jeanette F. Winther2,4 Henrik Hasle1

1 Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
2 Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark
3 Unit of Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
4 Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark
5 Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg
University Mainz, Mainz, Germany
6 Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
7 Department of Clinical Sciences, Lund University, Pediatric Oncology and Hematology, Skåne University Hospital, Lund, Sweden
8 Finnish Cancer Registry, Helsinki, Finland
9 Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
10 Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark

 

Tiedote osakkeenomistajille / Notice to shareholders

TIEDOTE INJEQ OYJ:N OSAKKEENOMISTAJILLE NOTICE TO SHAREHOLDERS OF INJEQ PLC
Read more »

News release on April 12, 2024

The share issue of Injeq Plc. ended on April 5, 2024, and the investment round did not achieve the goals […]
Read more »

Information to shareholders, March 22nd, 2024

Injeq has started a share issue. The maximum of the financing round is set at €3,000,000. If the €2,000,000 goal […]
Read more »

Injeq webinars by Dr Sauli Palmu and Dr Harri Sievänen

Injeq webinar videos are now available! Welcome to participate in Dr. Sauli Palmu’s lecture “Lumbar punctures in pediatric hemato-oncology” (part […]
Read more »

New distributor agreement with “GENFAX SRL”

We are pleased to announce that GENFAX is appointed as INJEQ’s exclusive distributor in Romania. We are confident that our […]
Read more »

Injeq webinar today, Thursday Feb 22nd, 2024

Welcome to the webinar “Innovation in lumbar punctures” on February 22nd, 2024, at 7:00 pm (Madrid time Zone)   Lecturers […]
Read more »